Derayah Venture Capital

Derayah Venture Capital is the venture arm of Derayah Financial, a Riyadh-based financial services group, and it operates as one of the more active homegrown VC platforms in the Saudi market. The firm invests across seed, Series A, and Series B with checks in the $1M to $5M range, focused on high-growth digital businesses across MENA with a clear emphasis on opportunities that benefit from the Vision 2030 regulatory and demand tailwinds inside Saudi Arabia itself. In healthcare, its bets concentrate in digital health and health IT software rather than therapeutics or hardware-heavy medtech, and the firm is willing to engage with AI-native plays as long as there is a credible commercial application rather than research-stage promise. The strategic advantage is access. Derayah is plugged into the Saudi institutional investor and family-office network, into the Ministry of Investment ecosystem, and into the broader Tadawul-listed corporate landscape, which matters enormously if your company needs to land enterprise contracts with Saudi hospital groups, insurers, or government health programs. For a foreign founder, that distribution muscle is genuinely difficult to replicate without a local partner. The right founder profile is a team with proven product-market fit elsewhere who is making a serious commitment to Saudi market entry, or a regionally founded company with a clear thesis on the Kingdom as its largest single market within three years. The wrong fit is a tourist who wants Saudi capital without a real local strategy; Derayah will see through that quickly. The right entry path is through Riyadh-based founder networks, through the financial advisory side of Derayah itself, or through warm introductions from Saudi-connected investors like Sanabil, Raed, or STV. Cold outreach via the website is a low-yield channel. When pitching, lead with the Saudi go-to-market specifically: which payer, which provider system, which regulator owns the policy you depend on, and which local partner you intend to commercialize with. Generic regional decks will underperform here. Caveats: Derayah’s healthcare portfolio is still being built, so founders should expect them to lean heavily on their financial-services lens rather than deep clinical operating expertise, and they will typically prefer to syndicate with healthcare-specialist co-investors. Treat Derayah as the partner who helps you land in Saudi Arabia, not as the sole healthcare-operating brain on your cap table.